KR20060023154A - 혈전증 치료용 응고 인자 xa 및 viia의 저해제로서의피롤리딘-1,2-디카르복실산-1-[(4-에티닐-페닐)-아미드]-2-[(페닐)-아미드] 유도체 - Google Patents
혈전증 치료용 응고 인자 xa 및 viia의 저해제로서의피롤리딘-1,2-디카르복실산-1-[(4-에티닐-페닐)-아미드]-2-[(페닐)-아미드] 유도체 Download PDFInfo
- Publication number
- KR20060023154A KR20060023154A KR1020057024102A KR20057024102A KR20060023154A KR 20060023154 A KR20060023154 A KR 20060023154A KR 1020057024102 A KR1020057024102 A KR 1020057024102A KR 20057024102 A KR20057024102 A KR 20057024102A KR 20060023154 A KR20060023154 A KR 20060023154A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- ethynylphenyl
- dicarboxamide
- oxo
- oxomorpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10327428.6 | 2003-06-18 | ||
| DE10327428A DE10327428A1 (de) | 2003-06-18 | 2003-06-18 | Ethinylprolinderivate |
| DE10329457.0 | 2003-07-01 | ||
| DE10329457A DE10329457A1 (de) | 2003-04-03 | 2003-07-01 | Ethinylprolinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060023154A true KR20060023154A (ko) | 2006-03-13 |
Family
ID=33553467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057024102A Withdrawn KR20060023154A (ko) | 2003-06-18 | 2004-05-27 | 혈전증 치료용 응고 인자 xa 및 viia의 저해제로서의피롤리딘-1,2-디카르복실산-1-[(4-에티닐-페닐)-아미드]-2-[(페닐)-아미드] 유도체 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7557222B2 (enExample) |
| EP (1) | EP1633346B1 (enExample) |
| JP (1) | JP5015593B2 (enExample) |
| KR (1) | KR20060023154A (enExample) |
| CN (1) | CN1809346A (enExample) |
| AR (1) | AR044818A1 (enExample) |
| AT (1) | ATE337000T1 (enExample) |
| AU (1) | AU2004246766B2 (enExample) |
| BR (1) | BRPI0411466A (enExample) |
| CA (1) | CA2529453C (enExample) |
| DE (1) | DE502004001289D1 (enExample) |
| ES (1) | ES2271894T3 (enExample) |
| MX (1) | MXPA05013536A (enExample) |
| PE (1) | PE20050229A1 (enExample) |
| TW (1) | TW200504012A (enExample) |
| WO (1) | WO2004110433A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004004731A1 (de) * | 2004-01-30 | 2005-08-18 | Merck Patent Gmbh | Harnstoffderivate |
| DE102004016605A1 (de) * | 2004-04-03 | 2005-10-20 | Merck Patent Gmbh | Thiocarbamoylproline |
| BRPI0618610A2 (pt) | 2005-11-16 | 2011-09-06 | Hoffmann La Roche | derivados de pirrolidina como inibidores de fator xa de coagulação |
| EP1818330A1 (de) | 2006-02-14 | 2007-08-15 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| CA2653753C (en) * | 2006-05-16 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Substituted prolinamides, production thereof and their use as medicaments |
| CA2691849A1 (en) * | 2007-06-28 | 2008-12-31 | Novartis Ag | Kallikrein 7 modulators |
| US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012058116A1 (en) | 2010-10-27 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9056859B2 (en) | 2010-10-29 | 2015-06-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| KR20140052034A (ko) | 2011-08-19 | 2014-05-02 | 머크 샤프 앤드 돔 코포레이션 | 신장 외수질 칼륨 채널의 억제제 |
| EP2755656B1 (en) | 2011-09-16 | 2016-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2013062892A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2013062900A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2773206B1 (en) | 2011-10-31 | 2018-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2013066714A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| US9777002B2 (en) | 2012-11-29 | 2017-10-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9604998B2 (en) | 2013-02-18 | 2017-03-28 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014150132A1 (en) | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
| WO2015065866A1 (en) | 2013-10-31 | 2015-05-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| JP6337750B2 (ja) * | 2013-11-22 | 2018-06-06 | 小野薬品工業株式会社 | 化合物 |
| WO2015107724A1 (ja) * | 2014-01-14 | 2015-07-23 | 大日本住友製薬株式会社 | 縮合5-オキサゾリジノン誘導体 |
| WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| CN109796439B (zh) * | 2019-01-18 | 2020-05-19 | 西安交通大学 | 一种羟脯氨酸类肽衍生物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU776053B2 (en) * | 2000-03-31 | 2004-08-26 | Astellas Pharma Inc. | Diazepan derivatives or salts thereof |
| US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| DE60221505D1 (de) | 2001-03-30 | 2007-09-13 | Millennium Pharm Inc | FAKTOR Xa BENZAMIDIN INHIBITOREN |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| DE102004014945A1 (de) * | 2004-03-26 | 2005-10-13 | Merck Patent Gmbh | Prolinylderivate |
-
2004
- 2004-05-27 AU AU2004246766A patent/AU2004246766B2/en not_active Ceased
- 2004-05-27 MX MXPA05013536A patent/MXPA05013536A/es not_active Application Discontinuation
- 2004-05-27 DE DE502004001289T patent/DE502004001289D1/de not_active Expired - Lifetime
- 2004-05-27 KR KR1020057024102A patent/KR20060023154A/ko not_active Withdrawn
- 2004-05-27 AT AT04735007T patent/ATE337000T1/de not_active IP Right Cessation
- 2004-05-27 CA CA2529453A patent/CA2529453C/en not_active Expired - Fee Related
- 2004-05-27 EP EP04735007A patent/EP1633346B1/de not_active Expired - Lifetime
- 2004-05-27 WO PCT/EP2004/005717 patent/WO2004110433A1/de not_active Ceased
- 2004-05-27 JP JP2006515798A patent/JP5015593B2/ja not_active Expired - Fee Related
- 2004-05-27 ES ES04735007T patent/ES2271894T3/es not_active Expired - Lifetime
- 2004-05-27 BR BRPI0411466-3A patent/BRPI0411466A/pt not_active Application Discontinuation
- 2004-05-27 US US10/561,227 patent/US7557222B2/en not_active Expired - Fee Related
- 2004-05-27 CN CNA2004800169550A patent/CN1809346A/zh active Pending
- 2004-06-14 PE PE2004000589A patent/PE20050229A1/es not_active Application Discontinuation
- 2004-06-16 TW TW093117389A patent/TW200504012A/zh unknown
- 2004-06-18 AR ARP040102129A patent/AR044818A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1633346A1 (de) | 2006-03-15 |
| CN1809346A (zh) | 2006-07-26 |
| ATE337000T1 (de) | 2006-09-15 |
| ES2271894T3 (es) | 2007-04-16 |
| AU2004246766A1 (en) | 2004-12-23 |
| BRPI0411466A (pt) | 2006-07-11 |
| AR044818A1 (es) | 2005-10-05 |
| DE502004001289D1 (de) | 2006-10-05 |
| PE20050229A1 (es) | 2005-04-12 |
| US20070093472A1 (en) | 2007-04-26 |
| US7557222B2 (en) | 2009-07-07 |
| AU2004246766B2 (en) | 2009-09-17 |
| WO2004110433A1 (de) | 2004-12-23 |
| JP2006527708A (ja) | 2006-12-07 |
| JP5015593B2 (ja) | 2012-08-29 |
| CA2529453C (en) | 2012-10-02 |
| CA2529453A1 (en) | 2004-12-23 |
| EP1633346B1 (de) | 2006-08-23 |
| TW200504012A (en) | 2005-02-01 |
| MXPA05013536A (es) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5015593B2 (ja) | 血栓症の治療のための凝固因子XaおよびVIIaの阻害剤としての1−[(4−エチニルフェニル)]−2−[(フェニル)]−ピロリジン−1,2−ジカルボキサミド誘導体 | |
| JP4705015B2 (ja) | カルボニル化合物 | |
| US20040038858A1 (en) | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | |
| JP4732757B2 (ja) | カルボキサミド | |
| JP4699985B2 (ja) | カルボキサミド誘導体及びその第Xa因子の阻害剤としての使用 | |
| JP4409941B2 (ja) | 第Xa因子阻害剤としてのフェニル誘導体 | |
| JP4567439B2 (ja) | カルボン酸アミド | |
| US20060135515A1 (en) | Heterocyclic amides and their use treating thromboembolic diseases and tumors | |
| US7763611B2 (en) | Aroylsemicarbazide derivatives against thromboembolic diseases | |
| US7427618B2 (en) | Ethynyl derivatives as factor Xa inhibitors | |
| SK1972003A3 (en) | Acetamide derivatives and the use thereof as inhibitors of coagulation factors XA and VIIA | |
| DE10327428A1 (de) | Ethinylprolinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20051215 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |